Related Experiment Videos
Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants
R Krishnan1, S Shankaran, M Krishnan
1Department of Pediatrics, Children's Hospital of Michigan, Detroit 48201, USA
Insights
Subcutaneous recombinant human erythropoietin in preterm infants shows rapid absorption and elimination. Dosing intervals should not be less than 48 hours for optimal therapeutic effect.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Biotechnology
Background:
- Recombinant human erythropoietin (EPO) is crucial for treating anemia in preterm infants.
- Understanding its pharmacokinetics is vital for effective dosing strategies.
Purpose of the Study:
- To investigate the pharmacokinetics of subcutaneous recombinant human erythropoietin in very low birth weight preterm infants.
- To determine appropriate dosing intervals based on absorption and elimination data.
Main Methods:
- 12 very low birth weight preterm infants (<32 weeks gestation) received a single subcutaneous dose of 300 IU/kg recombinant human erythropoietin.
- Serum EPO levels were monitored to calculate pharmacokinetic parameters: peak level, area under the curve, absorption half-life, and elimination half-life.
Main Results:
- A rapid increase in serum EPO levels was observed, with a median peak of 362.8 mIU/ml at 8.9 hours.
- Median absorption half-life was 5.5 hours and elimination half-life was 7.9 hours.
- No significant correlation was found between pharmacokinetic parameters and infant characteristics (birth weight, gestational age, sex, age, or weight at administration).
Conclusions:
- Subcutaneous recombinant human erythropoietin exhibits predictable pharmacokinetics in very low birth weight preterm infants.
- The findings support a minimum dosing interval of 48 hours for subcutaneous administration to maintain therapeutic levels.
Abstract:
The pharmacokinetics of recombinant human erythropoietin was studied in 12 very low birth weight preterm infants < 32 weeks of gestation after subcutaneous administration of 300 IU/kg at a postconceptional age of 34 (32-37) weeks and a weight of 1,505 (1330-1,740)g (median and range). The administration of recombinant human erythropoietin produced a rapid increase in serum erythropoietin levels with a peak level of 362.8 mIU/ml at 8.9 h. The area under the curve was 8,177.5 (4,597.1-15,453.0) mIU/ml/h, the absorption half-life was 5.5 (1.6-6.6) h, the elimination half-life was 7.9 (5.6-19.4) h, and the residence time was 19.6 (5.1-32.6) h (all values reflect median and range). There was no significant correlation between absorption and elimination half-life of erythropoietin and birth weight, gestational age, sex, and age and weight of the infants at the time of administration of erythropoietin. Based on absorption and elimination kinetics, the dosing interval for subcutaneous administration must not be < 48 h.